Format

Send to

Choose Destination
Cancer Discov. 2018 Sep;8(9):1066-1068. doi: 10.1158/2159-8290.CD-18-0798.

Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade.

Author information

1
Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
2
Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. Mark.Smyth@qimrberghofer.edu.au.
#
Contributed equally

Abstract

Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy. Cancer Discov; 8(9); 1066-8. ©2018 AACRSee related article by Chen et al., p. 1156.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center